Keep up to date on the care of patients with marginal zone lymphoma (MZL). Join Drs Flowers and Chen for an expert discussion of the types of MZL, current standard of care, and new targeted agents that are making a difference in the treatment of this rare indolent lymphoma.
1.0 AMA PRA Category 1 Credit™
1.0 Contact Hour
Jun 30, 2017
Jun 30, 2018
Robert Chen, MDCity of Hope
Duarte, California, United States
Christopher Flowers, MDEmory Winship Cancer Institute
Atlanta, Georgia, United States
- MZL disease characteristics
- Standard of care for newly diagnosed MZL
- New targeted agents in the treatment of relapsed or refractory MZL
This educational activity is specifically designed to meet the needs of hematologists, oncologists, pathologists, registered nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the care of patients with marginal zone lymphoma.
After successful completion of this educational activity, participants should be able to:
- Describe the unique biology and etiology of marginal zone lymphoma subtypes and how this influences diagnosis, prognosis, and therapeutic targeting
- Employ appropriate treatment approaches for patients with marginal zone lymphoma based on current treatment guidelines and emerging clinical trial data
- Evaluate recent clinical data investigating the efficacy and safety of novel treatment approaches for marginal zone lymphoma and the potential future role for these strategies in patient care
This activity is supported by educational grants from Celgene; Pharmacyclics LLC, an AbbVie Company; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs.
Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
A maximum of 1.0 contact hour may be earned for successful completion of this activity.
Annenberg Center for Health Sciences: https://www.annenberg.net/
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to Annenberg Center policy. Annenberg Center is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Dr Chen has disclosed that he has received consulting fees from Bristol-Myers Squibb, Merck, Pharmacyclics, and Seattle Genetics. He has performed contracted research for Bristol-Myers Squibb, Pharmacyclics, and Seattle Genetics. He has also received fees for non-CME services from Genentech and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.
Dr Flowers has disclosed that he has received consulting fees from AbbVie, Bayer, Celgene, Gilead Sciences, Optum Rx, Seattle Genetics, and Spectrum. He has performed contracted research and received research funding from AbbVie, Acerta, Celgene, Gilead Sciences, Infinity Pharmaceuticals, Janssen Pharmaceutical, Millennium/Takeda, Onyx Pharmaceuticals, Pharmacyclics, Spectrum, and the Burroughs Wellcome Fund. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Briana Betz, PhD (clinical content reviewer/planner) – no relevant financial relationships
- Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships
Charles W. Willis, MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.